Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can go much higher Apetf rises as Monkeypox rises
Time between PRs
8/2/21,
3 months
11/2/21
4 months
3/2/22.
5 months is today.
8/2/22
If this product is secure then it will be better than the current thievery:
“Hackers drain nearly $200 million from crypto startup in ‘free-for-all’ attack
PUBLISHED TUE, AUG 2 20227:46 AM EDT
Hackers yanked almost $200 million in crypto from Nomad, a so-called blockchain bridge.
Blockchain bridges allow users to transfer tokens from one network to another.
They’ve become a prime target for hackers seeking to swindle investors out of millions.
Billions of dollars of value have been wiped off the cryptocurrency market in recent months. Companies in the industry are feeling the pain. Lending and trading firms are facing a liquidity crisis and many firms have announced layoffs.
Billions of dollars of value have been wiped off the cryptocurrency market in recent months. Companies in the industry are feeling the pain. Lending and trading firms are facing a liquidity crisis and many firms have announced layoffs.
Yu Chun Christopher Wong | S3studio | Getty Images
Hackers drained almost $200 million in cryptocurrency from Nomad, a tool that lets users swap tokens from one blockchain to another, in yet another attack highlighting weaknesses in the decentralized finance space.
Nomad acknowledged the exploit in a tweet late Monday.
“We are aware of the incident involving the Nomad token bridge,” the startup said. “We are currently investigating and will provide updates when we have them.”
It’s not entirely clear how the attack was orchestrated, or if Nomad plans to reimburse users who lost tokens in the attack. The company, which markets itself as a “secure cross-chain messaging” service, wasn’t immediately available for comment when contacted by CNBC.
Blockchain security experts described the exploit as a “free-for-all.” Anyone with knowledge of the exploit and how it worked could seize on the flaw and withdraw an amount of tokens from Nomad — sort of like a cash machine spewing out money at the tap of a button.
It started with an upgrade to Nomad’s code. One part of the code was marked as valid whenever users decided to initiate a transfer, which allowed thieves to withdraw more assets than were deposited into the platform. Once other attackers cottoned on to what was going on, they deployed armies of bots to carry out copycat attacks.
“Without prior programming experience, any user could simply copy the original attackers’ transaction call data and substitute the address with theirs to exploit the protocol,” said Victor Young, founder and chief architect of crypto startup Analog.
How a $60 billion crypto collapse got regulators worried
“Unlike previous attacks, the Nomad hack became a free-for-all where multiple users started to drain the network by simply replaying the original attackers’ transaction call data.”
Sam Sun, research partner at crypto-focused investment firm Paradigm, described the exploit as “one of the most chaotic hacks that Web3 has ever seen” — Web3 being a hypothetical future iteration of the internet built around blockchain technology.
Nomad is what’s known as a “bridge,” a tool that lets users exchange tokens and information between different crypto networks. They’re used as an alternative to making transactions directly on a blockchain like Ethereum, which can charge users high processing fees when there’s lots of activity happening at once.
Instances of vulnerabilities and poor design have made bridges a prime target for hackers seeking to swindle investors out of millions. More than $1 billion in crypto assets has been stolen through bridge exploits so far in 2022, according to a report from crypto compliance firm Elliptic.
In April, a blockchain bridge called Ronin was exploited in a $600 million crypto heist, which U.S. officials have since attributed to the North Korean state. Some months later, Harmony, another bridge, was drained of $100 million in a similar attack.
Like Ronin and Harmony, Nomad was targeted through a flaw in its code — but there were a few differences. With those attacks, hackers were able to retrieve the private keys needed to gain control over the network and start moving out tokens. In Nomad’s case, it was much simpler than that. A routine update to the bridge enabled users to forge transactions and make off with millions’ worth of crypto.”
https://www.cnbc.com/2022/08/02/hackers-drain-nearly-200-million-from-crypto-startup-nomad.html
Millions put into the stock of another company representing 25% of the total shares of the other company, but what is stopping that percentage from being diluted? And cenntro is manufacturing the product for the other company for free?
Biggest volume since June 8 so far, something is in the works here soon
“Below is the share issuance summary of the financing activities of the Company during 2021 and 2020:
Date Shares of Common Stock Issued Cash Proceeds
from Share
Issuance Recipient(s)
of Shares
June 15, 2020 (1) 4,444,444 $ - Three shareholders
September 14, 2020 (2) 35,000 - One shareholder
November 18, 2020 (3) 457,312 - Eight shareholders
November 24, 2020 (4) 50,000 55,000 One shareholder
November 24, 2020 (5) 145,455 160,000 One shareholder
November 30, 2020 (6) 257,591 - Two shareholders
December 1, 2020 (7) 200,000 - One shareholder
December 1, 2020 (8) 300,000 - One shareholder
December 11, 2020 (9) 935,871 - Three shareholders
December 31, 2020 (10) 215,000 262,300 One shareholder
February 26, 2021 (11) 342,592 - Two shareholders
April 7, 2021 (12) 3,000,000 - One shareholder
April 7, 2021 (13) 60,000 - One shareholder
April 16, 2021 (14) 704,738 - One shareholder
July 14, 2021 (15) 232,659 - One shareholder
July 19, 2021 (16) 79,530 - Twenty five shareholders
July 26, 2021 (17) 281,498 - One shareholder
August 5, 2021 (18) 562,995 - One shareholder
August 12, 2021 (19) 643,423 - One shareholder
August 20, 2021 (20) 3,375,000 - One shareholder
August 24, 2021 (21) 3,370,000 - One shareholder
August 31, 2021 (22) 1,709,667 - One shareholder
August 31, 2021 (23) 1,075,000 - One shareholder
October 6, 2021 (24) 227,299 - One shareholder
October 8, 2021 (25) 1,042,725 - One shareholder
November 17, 2021 (26) 200,000 - One shareholder
1. The Company issued 4,444,444 shares of restricted Common Stock at a price of $0.90 per share, or a total of $4,000,000, to acquire a 4% interest in a 12.3-kilogram carved natural blue sapphire (the “Millennium Sapphire”).
2. The Company issued 35,000 shares of restricted Common Stock at a price of $1.00 per share, or a total of $35,000, to settle marketing expense to a marketing service provider, CorporateAds, LLC (“CorporateAds”).
3. The Company issued 457,312 shares of restricted Common Stock at a price of $1.64 per share, or a total of $749,992, to acquire 15% equity interests in Ata Plus Sdn. Bhd (“APSB”).
4. The Company issued and sold 50,000 shares of restricted Common Stock in a private placement to Mr. Seah Kok Wah at a price of $1.10 per share for cash proceeds of $55,000.
5. The Company issued and sold 145,455 shares of restricted Common Stock in a private placement to AG Opportunities Fund SPC-AG Pre-IPO Fund SP1 at a price of $1.10 per share for cash proceeds of $160,000.
6. The Company issued 257,591 shares of restricted Common Stock at a price of $1.596 per share, or a total of $411,120, to acquire 18% equity interests in New Business Media Sdn. Bhd (“NBMSB”).
57
7. The Company issued 200,000 shares of restricted Common Stock at a price of $1.567 per share, or a total of $313,400, to settle marketing expense to an investor relations agent, Mr. Dennis Burns.
8. The Company issued 300,000 shares of restricted Common Stock at a price of $1.2405 per share, or a total of $372,150, to settle consultancy fee to a business consultant, Mr. Daniel McKinney.
9.
The Company issued 685,871 shares of restricted Common Stock at a price of $1.458 per share, or a total of $1,000,000, to acquire 10% equity interests in First Bullion Holdings Inc. (“FBHI”).
The Company also issued 250,000 shares of restricted Common Stock at a price of $1.458 per share, or a total of $364,500 for purchase of an option to acquire an additional 8% of the issued and outstanding shares of FBHI, at an agreed valuation of FBHI equal to $20,000,000, which shall constitute partial payment for the option should the Company elect to exercise the option.
10. The Company issued and sold 215,000 shares of restricted Common Stock in a private placement to Ms. Wong Wai Hing Lena at a price of $1.22 per share for cash proceeds of $262,300.
11. The Company issued 342,592 shares of its restricted Common Stock at $2.7 per share, or a total of $925,000, to exercise the stock option pursuant to Section 2.2 of a stock purchase and option agreement dated October 19, 2020, between the Company, First Bullion Holdings Inc. (“FBHI”) and the shareholder of FBHI.
12. The Company subscribed for $7,206,000 worth of Class B shares of Innovest Energy Fund (the “Fund”) by issuing 3,000,000 shares of the Company’s restricted Common Stock at a price of $2.402 per share, or a total of $7,206,000 to the Fund.
13. The Company issued 60,000 shares of restricted Common Stock to a designee of the Fund at a price of $2.402 per share, or a total of $144,120 to settle a subscription fee to the Fund.
14. The Company fully repaid the convertible note issued to Streeterville Capital, LLC (“Streeterville”) on October 13, 2020 by issuance of 704,738 shares of its restricted Common Stock at a conversion price of $1 per share for settlement of the principal balance of $670,000 and accrued interest of $34,738, respectively on April 16, 2021. The market price of the Company’s Common Stock was $2.33 per share, or at a total value of $1,642,040, on April 16, 2021.
15. The Company partially repaid the convertible note issued to Streeterville on January 8, 2021 by issuance of 232,659 shares of its restricted Common Stock at a conversion price of $0.752175 per share for settlement of the principal balance of $175,000 on July 14, 2021. The market price of the Company’s Common Stock was $1.01 per share, or at a total value of $234,986, on July 14, 2021.
16. The Company issued 79,530 shares of its restricted Common Stock at a price of $0.87 per share, or a total of $69,191, to redeem 347,000 shares out of total 504,750 shares of preferred stock from 25 preferred stock shareholders of Greenpro Capital Village Sdn. Bhd.
17. The Company partially repaid the convertible note issued to Streeterville on January 8, 2021 by issuance of 281,498 shares of its restricted Common Stock at a conversion price of $0.621675 per share for settlement of the principal balance of $175,000 on July 26, 2021. The market price of the Company’s Common Stock was $0.93 per share, or at a total value of $261,793, on July 26, 2021.
18. The Company partially repaid the convertible note issued to Streeterville on January 8, 2021 by issuance of 562,995 shares of its restricted Common Stock at a conversion price of $0.621675 per share for settlement of the principal balance of $350,000 on August 5, 2021. The market price of the Company’s Common Stock was $0.8697 per share, or at a total value of $489,637, on August 5, 2021.
19. The Company partially repaid the convertible note issued to Streeterville on February 11, 2021 by issuance of 643,423 shares of its restricted Common Stock k at a conversion price of $0.621675 per share for settlement of principal balance of $400,000 on August 12, 2021. The market price of the Company’s Common Stock was $0.8101 per share, or at a total value of $521,237, on August 12, 2021.
20. The Company partially repaid the convertible note issued to Streeterville on February 11, 2021 by issuance of 3,375,000 shares of its restricted Common Stock at a conversion price of $0.621675 per share for settlement of principal balance of $2,098,153 on August 20, 2021. The market price of the Company’s Common Stock was $0.7599 per share, or at a total value of $2,564,662, on August 20, 2021.
21. The Company partially repaid the convertible note issued to Streeterville on February 11, 2021 by issuance of 3,370,000 shares of its restricted Common Stock at a conversion price of $0.621675 per share for settlement of principal balance of $2,095,045 on August 24, 2021. The market price of the Company’s Common Stock was $0.9164 per share, or at a total value of $3,088,268, on August 24, 2021.
22. The Company fully repaid the convertible note issued to Streeterville on January 8, 2021 by issuance of 1,709,667 shares of its restricted Common Stock at a conversion price of $0.621675 per share for settlement of the balance of principal of $960,000 and accrued interest of $102,857 on August 31, 2021. The market price of the Company’s Common Stock was $0.9573 per share, or at a total value of $1,636,664, on August 31, 2021.
23. The Company partially repaid the convertible note issued to Streeterville on February 11, 2021 by issuance of 1,075,000 shares of its restricted Common Stock at a conversion price of $0.621675 per share for settlement of principal balance of $668,301 on August 31, 2021. The market price of the Company’s Common Stock was $0.9573 per share, or at a total value of $1,029,097, on August 31, 2021.
24. The Company partially repaid the convertible note issued to Streeterville on February 11, 2021 by issuance of 227,299 shares of its restricted Common Stock at a conversion price of $0.43995 per share for settlement of principal balance of $100,000 on October 6, 2021. The market price of the Company’s Common Stock was $0.6761 per share, or at a total value of $153,676, on October 6, 2021.
25. The Company fully repaid the convertible note issued to Streeterville on February 11, 2021 by issuance of 1,042,725 shares of its restricted Common Stock at a conversion price of $0.43995 per share for settlement of the balance of principal of $154,989 and accrued interest of $303,758, respectively on October 8, 2021. The market price of the Company’s Common Stock was $0.6811 per share, or at a total value of $710,200, on October 8, 2021.
26. The Company issued 200,000 shares of its restricted Common Stock at a price of $1.0404 per share, or a total of $208,080, to settle marketing expense to Mr. Dennis Burns.
As of December 31, 2021, there were 78,671,688 shares of Common Stock issued and outstanding.
58
“
If there was a megatsunami wouldn’t that be defined as a crypt tide. 2 big asteroids, Erik Fin Man, Z ash… maybe it is just referring to the share price. They are supposedly competing against tik tok (“time”), just like in the movie Armageddon etc. chaos in the corporate suite lately.
Some Matrix decoding here:
Erik is “Er 911”
Finman is “End of Man”
BBIG is “2 Big or Too big” … to fail ?
Zash is “Z ash or ending in ashes”
Crypt Tide = “dead in the water”
Is this company trying to tell the world something about a future global event with the names it is selecting for its employees and affiliated entities ?
And imo it’s time to start reinvesting any money he collected monthly back into the company, the trend is towards legalization.
The more States that legalize the more chance at federal legalization same as same sex marriage, the consumer is confused about the legality of the industry in general, CBD weed and hemp etc, and their relation to State lines currently, even if you aren’t. The consumers are the buyers who want clarity and trust in a regulated industry.
Exploring Traditional Chinese medicine treatment for monkeypox through a 55% owned subsidiary, I like the chart but this is still at day one for any treatment to be presented in a PR
They also don’t appear to be experts in any medical field to guide that process, not saying they can’t:
“E-Home Household Service Holdings Limited is a household service company based in Fuzhou, China. The Company, through its website and WeChat platform "e???", provides integrated household services, including appliance installation and maintenance, housekeeping services, and Internet based home and senior care. For more information, visit the Company's website at http://www.ej111.com/ir.html.”
Accumulation distribution indicator tells the SP story, restricted shares diluting the share price even as the Williams indicator got stronger.
Unless something is filed tomorrow.
Valyria is the Dragon Capital
https://gameofthrones.fandom.com/wiki/Old_Valyria
DRG V for Valyria, V for ‘22
3 weeks until House of the Dragon
“Valyria's power was based on the taming and use of dragons in warfare, which they discovered in the chain of volcanoes known as the Fourteen Fires which were located around their homeland“
Look at the 5 year chart of DRGV and subtract 14 months from 8/21/22, you get 6/21/21 which on the chart is the center of the volcano.
Double the OS halve the SP, mathematics.
“Marijuana-Related Ballot Initiatives and Referenda:
POSTED ON JULY 29, 2022
Voters in several states will decide on marijuana-related ballot measures in November. Here is an update of where these efforts currently stand.
Arkansas
The group Responsible Growth Arkansas, led by former Arkansas Democratic House minority leader Eddie Armstrong, submitted more than double the signatures needed to qualify for the November ballot. On Friday, July 29, state officials verified that proponents had collected sufficient signatures. Now the state Board of Election Commissioners must approve the name and ballot title of the measure — at which time it will be certified for inclusion on the November ballot.
The proposed constitutional amendment allows adults 21 and older to purchase and possess up to an ounce of cannabis. Home cultivation would not be permitted, and the measure does not contain provisions to expunge past records or to provide for opportunities for social equity applicants.
Maryland
Lawmakers have approved a proposed Constitutional Amendment, House Bill 1, which asks voters: “Do you favor the legalization of adult–use cannabis in the State of Maryland?” State lawmakers also approved complementary legislation, HB 837, which defines marijuana possession limits and facilitates the automatic review and expungement of past criminal records.
If approved by voters, the referendum will take effect on July 1, 2023. At that time, adults will be legally permitted to possess up to 1.5 ounces of cannabis and/or 12 grams of cannabis concentrates. Possessing amounts between 1.5 ounces and 2.5 ounces would be subject to civil fines, while the possession of greater quantities would be subject to existing criminal penalties.
Lawmakers would still need to enact additional legislation next session to establish rules and regulations governing a legally regulated cannabis marketplace.
Missouri
A citizens’ initiative sponsored by the group Legal Missouri 2022 seeks to allow those 21 years and older to possess, purchase, consume, and cultivate marijuana while allowing those with nonviolent marijuana-related offenses to automatically have their criminal records expunged.
In May, representatives announced that they submitted more than 385,000 signatures on Sunday. That is more than double the total (171,592) necessary to place the proposed constitutional amendment on the ballot. However, because the proposed measure is a constitutional amendment, advocates are required to obtain a set percentage of signatures (eight percent) from six of the state’s eight congressional districts. Officials on Tuesday said that their initial counts only verified a sufficient number of signatures from the 1st, 2nd, 3rd and 5th districts.
In response, Dan Viets, Chair of the Legal Missouri 2022 Advisory Board and Executive Director for Missouri NORML, said, “We are in the process of working with the MO Secretary of State to show why local county clerks have undercounted valid signatures. We will have the appropriate number of validated signatures by the August 9th deadline.”
Nebraska
Nebraskans for Medical Marijuana (NMM) have submitted signatures supporting two separate measures for the 2022 ballot: 1.) The Medical Cannabis Patient Protection Act, which protects patients with serious health conditions and their caregivers from arrest, and 2.) The Medical Cannabis Commission Act, which regulates private businesses to provide medical cannabis to qualified patients.
In 2020, activists met the state’s signature requirement, but nonetheless had their measure struck from the ballot after the Nebraska Supreme Court issued an opinion finding that the initiative’s language violated the state’s single subject rule requirement. That is why this year’s effort is divided into two separate measures.
NMM turned in over 90,000 signatures for each of the medical cannabis legalization measures — just above the roughly 87,000 necessary to qualify them for the November ballot. In addition to the campaign’s slim margin, activists are also involved in a legal fight over the state’s ballot access laws.
North Dakota
Representatives from the group New Approach North Dakota have turned in 25,762 signatures to the Secretary of State’s office. That total is roughly 10,000 signatures above the number of signatures necessary (15,582) to qualify it for the 2022 ballot. Those signatures await verification from state officials.
The proposed measure would legalize the possession of one ounce of cannabis, up to four grams of cannabis concentrate, and up to 500 milligrams of cannabis in an infused product; and the cultivation of up to three cannabis plants. Historically, North Dakota has long had one of the highest marijuana arrests rates in the nation, despite having among the lowest reported marijuana use of any state.
Ohio
Advocates with the Coalition to Regulate Marijuana Like Alcohol have agreed to a settlement that will postpone any opportunity for voters to decide on a citizens’ initiated marijuana measure until November 2023. During the interim, NORML Appalachia of Ohio is working with local partners to target municipalities across the state for local measures to eliminate criminal and civil penalties for marijuana possession. In past years, numerous cities throughout the state have approved local measures depenalizing marijuana-related activities.
Oklahoma
Representatives from the New Approach PAC recently turned in over 164,000 signatures to the Secretary of State’s Office in an effort to place a binding, statewide marijuana legalization initiative (State Question 820) on the November ballot. That total is well above the number of signatures necessary (94,911) to qualify for the 2022 ballot.
SQ 820 allows adults 21 and older to purchase and possess up to one ounce of cannabis and grow up to six mature plants and six seedlings for personal use. The measure also provides pathways for the resentencing and/or expunging of criminal records. Because SQ 820 does not alter the Oklahoma Constitution, fewer signatures are needed to place the measure on the November ballot.
Earlier this year, Republican Gov. Kevin Stitt claimed that voters were misled when they approved medical cannabis legalization. In June, he signed legislation into law (House Bill 3208) imposing a moratorium on the issuance of any new cannabis business licenses. While campaigning for Governor, Stitt said that he personally opposed legalizing marijuana for adults and that he would campaign against it, but he also acknowledged that he would respect the will of the voters should they decide in favor of it.
South Dakota
For the second consecutive election, voters in South Dakota will decide on a ballot measure to legalize marijuana use by those age 21 or older. In May, the Secretary of State’s office confirmed that advocates had secured the necessary number of signatures to place Initiated Measure 27 on the November ballot. It permits adults to possess (up to one ounce), home-cultivate (up to three mature plants), and/or transfer without remuneration limited quantities of cannabis. The measure does not seek to establish a regulatory framework governing the licensed production and retail sale of marijuana.
Advocates limited the scope of the measure after a previous, more comprehensive measure that had been approved by voters in 2020 was struck down by the state Supreme Court.
Texas
The only way to change marijuana laws statewide in Texas is through the legislature, which meets every two years for approximately 140 days. However, localities have discretion for implementing first chance and/or diversion programs and more. For cities that are “home rule cities”, they can also pass any regulations or laws that it deems necessary unless the state law prohibits it.
Ground Game Texas is working in several home rule cities across Texas to depenalize personal cannabis possession. Recently, voters in the city of Austin, Texas overwhelmingly approved a local ballot measure, Proposition A, depenalizing marijuana possession and prohibiting police from executing ‘no knock’ warrants.
Similar efforts in the city of Elgin (pop. 10,231), Denton (pop. 139,734), San Marcos (pop. 64,053), and Killeen (pop. 148,573) have qualified for the November ballot. Harker Heights (pop. 31,657) area activists have also submitted their signatures for verification with the hopes of being on the November ballot. Learn about volunteer opportunities.”
https://norml.org/blog/2022/07/29/marijuana-related-ballot-initiatives-and-referenda-july-29th-2022-update/
“Marijuana-Related Ballot Initiatives and Referenda:
POSTED ON JULY 29, 2022
Voters in several states will decide on marijuana-related ballot measures in November. Here is an update of where these efforts currently stand.
Arkansas
The group Responsible Growth Arkansas, led by former Arkansas Democratic House minority leader Eddie Armstrong, submitted more than double the signatures needed to qualify for the November ballot. On Friday, July 29, state officials verified that proponents had collected sufficient signatures. Now the state Board of Election Commissioners must approve the name and ballot title of the measure — at which time it will be certified for inclusion on the November ballot.
The proposed constitutional amendment allows adults 21 and older to purchase and possess up to an ounce of cannabis. Home cultivation would not be permitted, and the measure does not contain provisions to expunge past records or to provide for opportunities for social equity applicants.
Maryland
Lawmakers have approved a proposed Constitutional Amendment, House Bill 1, which asks voters: “Do you favor the legalization of adult–use cannabis in the State of Maryland?” State lawmakers also approved complementary legislation, HB 837, which defines marijuana possession limits and facilitates the automatic review and expungement of past criminal records.
If approved by voters, the referendum will take effect on July 1, 2023. At that time, adults will be legally permitted to possess up to 1.5 ounces of cannabis and/or 12 grams of cannabis concentrates. Possessing amounts between 1.5 ounces and 2.5 ounces would be subject to civil fines, while the possession of greater quantities would be subject to existing criminal penalties.
Lawmakers would still need to enact additional legislation next session to establish rules and regulations governing a legally regulated cannabis marketplace.
Missouri
A citizens’ initiative sponsored by the group Legal Missouri 2022 seeks to allow those 21 years and older to possess, purchase, consume, and cultivate marijuana while allowing those with nonviolent marijuana-related offenses to automatically have their criminal records expunged.
In May, representatives announced that they submitted more than 385,000 signatures on Sunday. That is more than double the total (171,592) necessary to place the proposed constitutional amendment on the ballot. However, because the proposed measure is a constitutional amendment, advocates are required to obtain a set percentage of signatures (eight percent) from six of the state’s eight congressional districts. Officials on Tuesday said that their initial counts only verified a sufficient number of signatures from the 1st, 2nd, 3rd and 5th districts.
In response, Dan Viets, Chair of the Legal Missouri 2022 Advisory Board and Executive Director for Missouri NORML, said, “We are in the process of working with the MO Secretary of State to show why local county clerks have undercounted valid signatures. We will have the appropriate number of validated signatures by the August 9th deadline.”
Nebraska
Nebraskans for Medical Marijuana (NMM) have submitted signatures supporting two separate measures for the 2022 ballot: 1.) The Medical Cannabis Patient Protection Act, which protects patients with serious health conditions and their caregivers from arrest, and 2.) The Medical Cannabis Commission Act, which regulates private businesses to provide medical cannabis to qualified patients.
In 2020, activists met the state’s signature requirement, but nonetheless had their measure struck from the ballot after the Nebraska Supreme Court issued an opinion finding that the initiative’s language violated the state’s single subject rule requirement. That is why this year’s effort is divided into two separate measures.
NMM turned in over 90,000 signatures for each of the medical cannabis legalization measures — just above the roughly 87,000 necessary to qualify them for the November ballot. In addition to the campaign’s slim margin, activists are also involved in a legal fight over the state’s ballot access laws.
North Dakota
Representatives from the group New Approach North Dakota have turned in 25,762 signatures to the Secretary of State’s office. That total is roughly 10,000 signatures above the number of signatures necessary (15,582) to qualify it for the 2022 ballot. Those signatures await verification from state officials.
The proposed measure would legalize the possession of one ounce of cannabis, up to four grams of cannabis concentrate, and up to 500 milligrams of cannabis in an infused product; and the cultivation of up to three cannabis plants. Historically, North Dakota has long had one of the highest marijuana arrests rates in the nation, despite having among the lowest reported marijuana use of any state.
Ohio
Advocates with the Coalition to Regulate Marijuana Like Alcohol have agreed to a settlement that will postpone any opportunity for voters to decide on a citizens’ initiated marijuana measure until November 2023. During the interim, NORML Appalachia of Ohio is working with local partners to target municipalities across the state for local measures to eliminate criminal and civil penalties for marijuana possession. In past years, numerous cities throughout the state have approved local measures depenalizing marijuana-related activities.
Oklahoma
Representatives from the New Approach PAC recently turned in over 164,000 signatures to the Secretary of State’s Office in an effort to place a binding, statewide marijuana legalization initiative (State Question 820) on the November ballot. That total is well above the number of signatures necessary (94,911) to qualify for the 2022 ballot.
SQ 820 allows adults 21 and older to purchase and possess up to one ounce of cannabis and grow up to six mature plants and six seedlings for personal use. The measure also provides pathways for the resentencing and/or expunging of criminal records. Because SQ 820 does not alter the Oklahoma Constitution, fewer signatures are needed to place the measure on the November ballot.
Earlier this year, Republican Gov. Kevin Stitt claimed that voters were misled when they approved medical cannabis legalization. In June, he signed legislation into law (House Bill 3208) imposing a moratorium on the issuance of any new cannabis business licenses. While campaigning for Governor, Stitt said that he personally opposed legalizing marijuana for adults and that he would campaign against it, but he also acknowledged that he would respect the will of the voters should they decide in favor of it.
South Dakota
For the second consecutive election, voters in South Dakota will decide on a ballot measure to legalize marijuana use by those age 21 or older. In May, the Secretary of State’s office confirmed that advocates had secured the necessary number of signatures to place Initiated Measure 27 on the November ballot. It permits adults to possess (up to one ounce), home-cultivate (up to three mature plants), and/or transfer without remuneration limited quantities of cannabis. The measure does not seek to establish a regulatory framework governing the licensed production and retail sale of marijuana.
Advocates limited the scope of the measure after a previous, more comprehensive measure that had been approved by voters in 2020 was struck down by the state Supreme Court.
Texas
The only way to change marijuana laws statewide in Texas is through the legislature, which meets every two years for approximately 140 days. However, localities have discretion for implementing first chance and/or diversion programs and more. For cities that are “home rule cities”, they can also pass any regulations or laws that it deems necessary unless the state law prohibits it.
Ground Game Texas is working in several home rule cities across Texas to depenalize personal cannabis possession. Recently, voters in the city of Austin, Texas overwhelmingly approved a local ballot measure, Proposition A, depenalizing marijuana possession and prohibiting police from executing ‘no knock’ warrants.
Similar efforts in the city of Elgin (pop. 10,231), Denton (pop. 139,734), San Marcos (pop. 64,053), and Killeen (pop. 148,573) have qualified for the November ballot. Harker Heights (pop. 31,657) area activists have also submitted their signatures for verification with the hopes of being on the November ballot. Learn about volunteer opportunities.”
https://norml.org/blog/2022/07/29/marijuana-related-ballot-initiatives-and-referenda-july-29th-2022-update/
“9:00a ET 7/11/2022 - PR Newswire
Genetec Recognizes Remark Holdings, Inc. as a Silver Partner in the Development Acceleration Program
Companies Will Jointly Market AI Solutions Based Upon Remark's Smart Safety Platform as a Feature Set for Genetec Security Center Customers
Remark Holdings, Inc. (NASDAQ: MARK), a diversified global technology company with leading artificial intelligence ("AI") solutions and digital media properties, today announced that it has been accepted as a Silver Partner in Genetec's Development Acceleration Program ("DAP"). Remark's Smart Safety Platform ("SSP"), a leading video analytics solution, is now available for Genetec's Security Center customers.
"Genetec is a global market leader in video management software via their flagship product, Security Center. We are pleased to have been accepted as a Silver Integration Partner, a distinction that recognizes the value added by our AI-powered SSP," noted Kai-Shing Tao, Chairman and Chief Executive Officer of Remark Holdings. "Our recent customer wins in the arena and transportation segments include our first customers using Genetec's Security Center who, along with the many other potential customers using Security Center, can seamlessly benefit from the full features of our SSP."
The strategic relationship between Remark and Genetec allows current Genetec Security Center users to access the features of Remark's SSP as a seamless plug-in that provides advanced features built on an AIoT architecture, enabling edge computing on AI boxes and servers for both on-premises and cloud deployment scenarios with real-time processing, reduced hardware costs, and reduced storage and bandwidth requirements, thereby leading to greater flexibility and cost efficiency for large-scale deployments.
The SSP plug-in for Security Center: 1) generates real-time alerts for proactive security and safety, such as for intrusions or trespassing, people counting/crowd detection, loitering, unattended bags, anti-social behavior such as vandalism, presence of fire and smoke, and inappropriate vehicular activity with license plate number detection; 2) assists with intelligent forensic investigation by providing for meta-data searches utilizing physical and object recognition attributes to speed up the investigation process; and 3) provides dashboards with actionable insights and reports for daily monitoring and pattern spotting.“
Elon Musk buy Bebuzee instead and compete with Twitter as the underdog, same as Tesla did, he didn’t buy Ford or Honda etc., he competed with Ford and Honda etc, and won.
8 mile (August, 8th month, mile), includes the song Lose (Lus) Yourself from Eminem (MM(market maker)), his character in the film (illustro picture) is Rabbit, and 2023 is the Chinese year of the Rabbit. A mile is the equivalent to 5280 lucky rabbit’s feet, and exactly 5 months 2 weeks and 8 days from tomorrow the year of the Rabbit begins (January 22, 2023)
https://www.travelchinaguide.com/intro/social_customs/zodiac/rabbit.htm
The 6 month consolidation period is over on the 6 month chart, ILUS can move to new highs beginning Monday and trending higher until 2024 at least imo.
There is value to buy Taug because the price of Taug might be lower than any manufacturer’s price, especially if distribution deals currently in place could be strengthened which they likely would be if a bigger company bought Taug, the new and increased funding would promise the manufacturer more manufacturing which allows the manufacturer to stay more independent as well. This is why some firms might buy a small company in the US before they bought its factories in China, it might take longer all things being equal and all things are not equal across the financial and legal boundaries of States and countries. Any company in general that has an e-commerce business in place has value to bigger companies that see opportunity to ramp it up, same with companies that are revenue effective but in too much debt.
They can provide the public with billions in advertising the public won’t believe it until the media reports it is legal.
The FDA stated SIGA’s Tpoxx has no human data to show it is effective against the current virus.
“Therapeutics
There is no FDA-approved or authorized medicine for the treatment of monkeypox disease; however, TPOXX (tecovirimat), an antiviral medication, is being made available through the CDC under an FDA authority called Expanded Access or “compassionate use.” The FDA continues to work with the CDC to streamline their Expanded Access Program for monkeypox to facilitate access.
There are currently no human data demonstrating the efficacy of TPOXX for the treatment of monkeypox, or the safety and pharmacokinetic profile (which helps us understand what the human body does to a drug). Although expanded access program is available, conducting randomized, controlled trials to assess TPOXX’s safety and efficacy in humans with monkeypox infections is essential.”
https://www.fda.gov/news-events/press-announcements/fda-provides-update-agency-response-monkeypox-outbreak
Their SP dropped from 22 to 14 on the news, it’s not yet a player in this story until and if it can prove effective. Those that bought in at 5.00 at sold at 20, good trade on the rumor that it might work eventually. They can also see that Govx is the market replacement for their ineffectiveness and are trying to hold off selling so they themselves can sell for a profit and jump in to Govx at a lower price ( they hope to cause with tweets ). Supply low and demand high for vaccines, and increasing.
“12:05p ET 5/31/2022 - Benzinga
GeoVax Tweets 'Previous peer reviewed publications have validated that the GeoVax constructs of MVA also provide protection against monkeypox.'
Previous peer reviewed publications have validated that the GeoVax constructs of MVA also provide protection against monkeypox. https://t.co/hyI5tp4JAK#MVA #validated #safety #durability #vaccine #monkeypox #infectiousdisease $GOVX pic.twitter.com/wXUYDzNgMh
— GeoVax, Inc. (@Geovax_News) May 31, 2022
A “V” (‘22nd letter) has a single point, they should get a contract with an entire State or country education or health system in the near term if Box Air provided positive comparative health results to non-box air systems. Wuhan labs could use air purifiers as well, for example. Solar demand should increase toward winter if fuel prices remain high, look to Europe.
Patent is a key to major revenue, moving into major US sports season now, could get very interesting here. V is 22. VS is 22 1 9, September 1?
“is already very legal and can be sold via interstate commerce.”
You know that, but the general public doesn’t. The general public are the consumers.
“Just wait until there is chewing gum, coming from the big, well financed players, which is laced with CBD and THC or just THC!!!”
Have a big player buy this company then for .03 cents a share, it already has chewing gum and sales. Oh, maybe that is why the annual report wasn’t filed on time because Taug is in the process of being sold to a bigger company and there is a NDA. If there is a sense in the industry that Congress can’t get their job done then sell the company, and buy millions of shares in advance of that sales process which is exactly what occurred this year as per the PR and could occur soon again.
It’s the matrix code I think
So none of the warrants increase the OS, what do you mean by “this”
.36 by August 10th , then maybe a buy
Delete 6 billion common shares, way too many.
HVCW SECURITY DETAILS
Share Structure
Market Cap Market Cap
1,969,452
07/29/2022
Authorized Shares
25,000,000,000
07/08/2022
Outstanding Shares
6,564,838,949
07/08/2022
Restricted
100,003,867
07/08/2022
Unrestricted
6,464,835,082
07/08/2022
Held at DTC
6,088,363,082
07/08/2022
Float
Not Available
Par Value
0.0001
“Italy’s BKT Series on Helbiz Live to be Available on Amazon Prime Video
July 27 2022 - 09:00AM
Business Wire
Helbiz Live is available within Amazon Prime Video Channels on all devices and smart TVs in Italy
Helbiz Media, a division of the Nasdaq-listed Helbiz Inc.(HLBZ), announces that Helbiz Live, including the upcoming season of the Italian BKT Series, is available on Amazon Prime Video Channels in Italy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220727005167/en/
The first day of the season on Helbiz Live within Amazon Prime Video will start with a special event: Genoa CFC vs SS Lazio on July 27 at 6 p.m. CET. Genoa CFC, Italy's oldest football team, will face off against SS Lazio, one of the most competitive teams from Serie A, in a friendly match. Helbiz Live will broadcast the match live, available to all fans for free. The Serie BKT Championship will start on August 12 with the opening match featuring Parma against Bari.(Graphic: Business Wire)
The first day of the season on Helbiz Live within Amazon Prime Video will start with a special event: Genoa CFC vs SS Lazio on July 27 at 6 p.m. CET. Genoa CFC, Italy's oldest football team, will face off against SS Lazio, one of the most competitive teams from Serie A, in a friendly match. Helbiz Live will broadcast the match live, available to all fans for free. The Serie BKT Championship will start on August 12 with the opening match featuring Parma against Bari.(Graphic: Business Wire)
Fans in Italy will easily be able to subscribe to Helbiz Live directly through Prime Video Channels and watch all live and on-demand matches of the 2022/2023 BKT Series Championship, including up to 390 games between the regular season, playoffs and playouts. It will also feature a series of exclusive sports and entertainment content from Chiara Giuffrida, the new face and host of Helbiz Live.
"Our priority is to be on the fan’s side by constantly working to make our service easily accessible on all devices,” said Matteo Mammì, CEO of Helbiz Media. “A notable agreement like this, with a global partner such as Amazon, was born precisely in response to this focus on the customer, who are able to follow the BKT Series Championship and all the other incredible sports and entertainment content we offer through Amazon Prime Video. Through Amazon Prime Video, our service will be available to many potential new customers in Italy who can easily subscribe to Helbiz Live with a couple of clicks.”
The first day of the season on Helbiz Live within Amazon Prime Video will start with a special event: Genoa CFC vs SS Lazio on July 27 at 6 p.m. CET. Genoa CFC, Italy's oldest football team, will face off against SS Lazio, one of the most competitive teams from Serie A, in a friendly match.
Helbiz Live will broadcast the match live, available to all fans for free. The Serie BKT Championship will start on August 12 with the opening match featuring Parma against Bari.
”
Four days in a row closing below the lower bollinger band on the one month chart, a close above that band and it could rocket higher at the rate of 4x a normal increase, it is mid-summer, gas is expensive, and the stock can be hot as hel..biz.
Scissor X and you get 2 V’s (2 22s, February 2022), the top V points down representing the SP from February 1 to August 1, the bottom V points up representing August 1 to February 1 2023, put the v’s together you get v^ as can be typed on a keyboard, (V carrot, 2023 is the year of the rabbit which eats carrots traditionally). Closing Price on February 1, 2022 was … .15. In theory therefore the price on February 1, 2023 will be higher than .15, why that is only the future would confirm. The closing SP was .31 on 11/24/2021. That is my exact guess at the SP on 2/1/23.
“Senate Committee Calls For Marijuana, Psychedelics And Hemp Reforms In Draft Spending LegislationPublished 20 hours ago on July 29, 2022
Senate Democrats have released a massive package of spending bills and related reports for the 2023 Fiscal Year, including numerous provisions that deal with issues such as state-level medical marijuana protections, psychedelics research and U.S. Department of Veterans Affairs (VA) cannabis policy.
The newly unveiled legislation from Senate Appropriations Committee Chairman Patrick Leahy (D-VT) contains many familiar drug policy sections, some of which overlap with spending measures that were approved in the House this month. Both chambers have also notably excluded an existing rider that has blocked Washington, D.C. from implementing a system of legal marijuana sales—a decision that’s already drawn the ire of Senate Republicans.
And while the House has previously addressed psychedelic issues through the appropriations process, this marks the first time that the Senate has included report language that urges federal agencies to promote research into the therapeutic potential of substances like psilocybin.
Advocates hoped that the Senate would insert language in the base bill that would provide broad protections for all state and U.S. territory cannabis programs, but as introduced, the legislation only maintains a longstanding rider preventing the use of Justice Department funds to interfere in medical cannabis programs.
Of course, it’s still possible that the Senate could adopt the more holistic language as an amendment down the line, as the House did again this year. But Republican appropriators have already signaled that they will put up a fight over modest cannabis reforms such as the exclusion of the D.C. marijuana rider.
Senate Appropriations Committee Vice Chairman Richard Shelby (R-AL) voiced opposition to the removal of “legacy riders” in a statement on Thursday, for example, specifically complaining that the legislation “clears the way for marijuana legalization in Washington, D.C., and allows federal funds to be used to finance needle exchange programs in the nation’s capital without restriction.”
The newly released documents have not yet been approved by the Appropriations Committee, and at this point represent a starting point for further negotiations as proposed by the chairman. It remains to be seen to what extent the panel will go through a full markup process for each individual spending bill ahead of the end of the fiscal year on September 30.
Here’s a breakdown of the drug policy provisions of the Senate Appropriations Committee spending bills and reports:
Medical marijuana programs in states and U.S. territories would continue to be protected from Justice Department interference under a rider for the Commerce, Justice, Science, and Related Agencies (CJS) spending bill that’s been annually renewed each year since 2014.
“SEC. 531. None of the funds made available under this Act to the Department of Justice may be used, with respect to any of the States of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming, or with respect to the District of Columbia, the Commonwealth of the Northern Mariana Islands, the United States Virgin Islands, Guam, or Puerto Rico, to prevent any of them from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana.”
A summary of the CJS spending legislation from the committee majority touts the provision, though it’s mischaracterized.
“This bill again contains language preventing the Justice Department from interfering with states that have medical marijuana laws, ensuring that the prescribing and dispensing of medical marijuana in those states is both legal and regulated,” the summary states. (The rider doesn’t ensure that the programs are legal or regulated; it simply restricts the use of DOJ funds to enforce the ongoing federal prohibition that in fact continues to remain on the books.)
“Patients and doctors in states that have approved medical marijuana need to know that they are safe from arrest and prosecution by the Federal government,” the summary says.
One of the more novel sections of the appropriations legislation addresses psychedelics research, with the committee urging federal health agencies to keep funding studies that look into the medical value of substances like psilocybin.
“Psychedelic Research.—The Committee encourages NIH to continue research funding for psychedelic medicines development and encourage psychedelic research at the NIH Clinical Center. The Committee also encourages NIH to continue to work with FDA in developing and supporting public private collaborations, including academic researchers and medicine developers, to advance all forms of psychedelic research for therapeutic purposes.”
Another new section addresses VA cannabis policy, with the committee expressing “concerns” about the department interfering in veterans’ medical marijuana access, including by preventing VA doctors from issuing cannabis recommendations to patients.
“Medical Cannabis.—The Committee has concerns with any effort by VA to interfere with the ability of a veteran to participate in a medicinal marijuana program approved by a State, deny any services from the Department to a veteran who is participating in such a program, and limit or interfere with the ability of a healthcare provider of the Department to make appropriate recommendations, fill out forms, or take steps to comply with such a program.”
As noted, the appropriations legislation omits what’s known as the “Harris rider,” after Rep. Andy Harris (R-MD), that has blocked D.C. from using its local dollars to allow commercial cannabis sales even though voters approved adult-use legalization in 2014.
Sen. Chris Van Hollen (D-MD), chair of the Appropriations Financial Services and General Government (FSGG) Subcommittee, highlighted that decision, saying that the bill “will increase transparency in political fundraising, strengthen our election security, remove harmful legacy riders that unfairly restrict the District of Columbia’s ability to fund reproductive services and regulate cannabis, and much more.”
While it remains to be seen whether that provision will stay out of the final package that’s delivered to the president’s desk, the mayor of D.C. did recently sign a bill that allows people to self-certify as medical cannabis patients in the District, effectively circumventing the congressional barrier. Also, for what it’s worth, President Joe Biden’s past two budget requests have maintained the Harris rider despite broad Democratic opposition.
There are several research-focused report sections dealing with marijuana. Appropriators directed federal agencies to take steps to support studies into the Schedule I substances and emphasized their ongoing concerns about research barriers under federal prohibition.
“Marijuana Research.—The Committee is concerned that marijuana policies on the Federal level and in the States (medical marijuana, recreational use, etc.) are being changed without the benefit of scientific research to help guide those decisions. NIH is encouraged to continue supporting a full range of research on the health effects of marijuana and its components, including research, to understand how marijuana policies affect public health.”
…
“Cannabis Research.—Although concrete steps have been taken towards ameliorating the regulatory and supply issues hampering cannabis research in the U.S., funding levels have not kept pace with widespread use of cannabis and substantial clinical interest in the field. Cannabis is fully legal in 18 States and the District of Columbia, effectively so in 20 others that permit some form of medical marijuana, and consumed by nearly half of American teens and adults at some time in their lives, yet there is surprisingly little information about its effects on body chemistry and cognition. Meanwhile, limited data exists on the clinical efficacy of cannabis despite this use. The Committee encourages NIH to continue to fund cannabis research, with an emphasis on medical cannabis therapeutic development for patients. The Committee encourages NIH to expand its current research agenda across its institutes, including additional research on higher potency THC, alternative cannabis formulations and extracts, and additional minor cannabinoids. The Committee also encourages NIH to continue to conduct research on the potential medical uses of cannabis, such as chronic pain, appetite stimulation, immune diseases, cancer, metabolic and digestive disorders, epilepsy, glaucoma, multiple sclerosis, sleep disorders, and a variety of mental health conditions such as anxiety and PTSD. In addition, the Committee recognizes the benefits of cross-institute collaboration in the HEAL Initiative. Therefore, the Committee urges NIH to take an integrated approach to cannabis research, including by forming a cross-institute research group.”
…
Barriers to Research.—The Committee is concerned that restrictions associated with Schedule I of the Controlled Substance Act effectively limits the amount and type of research that can be conducted on certain Schedule I drugs, especially opioids, marijuana or its component chemicals, and new synthetic drugs and analogs. At a time when we need as much information as possible about these drugs, including research on their therapeutic potential and on overdose reversal agents, we should be lowering regulatory and other barriers to conducting this research. The Committee appreciates NIDA’s completion of a report on the barriers to research that result from the classification of drugs and compounds as Schedule I substances, including the challenges researchers face as a result of limited access to sources of marijuana including dispensary products.
The spending report for the U.S. Department of Health and Human Service (HHS) also talks about exploring alternatives to opioids, which appropriators say should include studies into the therapeutic potential of kratom, a plant associated with pain-relieving qualities.
“Combating Opioid Overdoses.—According to CDC, there were more than 107,000 drug overdose deaths during the 12-month period ending in January 2022. The Committee notes and commends NIDA for its funding of research to examine the potential for kratom to reduce opioid use among people with opioid use disorder, given kratom’s reduced addiction and overdose liability as compared to opioids.”
The House spending legislation also tackles the issue of kratom research.
The new Senate proposals also contain ample report language on hemp and its derivatives like CBD, including a mandate that the Food and Drug Administration (FDA) implement enforcement discretion guidance for the marketing of the legal cannabinoid as the agency continues to look into rulemaking.
“Cannabis and Cannabis Derivatives.—The Committee notes that budget did not request additional resources for Cannabis and Cannabis Derivatives activities, and therefore directs the FDA to maintain funding levels to support regulatory activities, including developing policy, and for the FDA to continue to perform its existing regulatory responsibilities, including review of product applications, inspections, enforcement, and targeted research for cannabis-derived substances, such as cannabidiol [CBD]. Within 90 days of enactment of this Act, the FDA shall issue a policy of enforcement discretion with regard to certain products containing CBD meeting the definition of hemp as defined by section 297A of the Agricultural Marketing Act of 1964 (7 U.S.C. 1639). Such enforcement discretion shall be in effect until the FDA establishes a process for stakeholders to notify the FDA of use of CBD in products that include safety studies for intended use per product and 112 makes a determination about such product. In addition, the FDA is encouraged to consider existing and ongoing medical research related to CBD that is being undertaken pursuant to an Investigational New Drug application in the development of a regulatory pathway for CBD in products under the jurisdiction of the FDA and to ensure that any future regulatory activity does not discourage the development of new drugs. The Committee also encourages the FDA to partner with an academic institution to expand sampling studies of CBD products currently on the market.”
The CJS bill, as well as appropriations legislation for the U.S. Department of Agriculture (USDA), contains longstanding provisions to safeguard state hemp programs from interference.
“SEC. 530. None of the funds made available by this Act may be used in contravention of section 7606 (‘Legitimacy of Industrial Hemp Research’) of the Agricultural Act of 2014 (Public Law 113–79) by the Department of Justice or the Drug Enforcement Administration.”
…
“SEC. 741. None of the funds made available by this Act or any other Act may be used—
(1) in contravention of section 7606 of the Agricultural Act of 2014 (7 U.S.C. 5940), subtitle G of the Agricultural Marketing Act of 1946, or section 10114 of the Agriculture Improvement Act of 2018; or
(2) to prohibit the transportation, processing, sale, or use of hemp, or seeds of such plant, that is grown or cultivated in accordance with section 7606 of the Agricultural Act of 2014 or subtitle G of the Agricultural Marketing Act of 1946, within or outside the State in which the hemp is grown or cultivated.”
The draft also says the committee is concerned about existing regulations for the federally legal crop such as an “arbitrary” THC limit and limited industry access to certain USDA grant and insurance programs. It also encouraged DEA to continue developing field testing technology to help law enforcement distinguish hemp from marijuana.
“Hemp.—The Committee is concerned that the level of allowable THC content in hemp may be arbitrary and pose a burden on hemp producers that is not supported by scientific evidence. The Committee directs USDA to work with the Department of Health and Human Services and the Drug Enforcement Administration to study and report to Congress on whether there is scientific basis for the current limit of 0.3 percent THC in hemp and suggest alternative levels if necessary.
The Committee is concerned that producers of high value, horticultural hemp are being prevented from accessing USDA programs designed for specialty crops, including the Specialty Crop Block Grants and crop insurance. Within 90 days of enactment of this Act, the Committee directs the Secretary to establish a dual designation for hemp as a specialty crop based on the manner and purpose for which it is grown.”
…
“Hemp Testing Technology.—The Agriculture Improvement Act of 2018 (Public Law 115–334) removed hemp and its derivatives from the Controlled Substances Act (Public Law 91–513, as amended), and authorized the production, consumption, and sale of hemp and hemp-derived products in the United States. The Act requires random testing to ensure hemp meets the definition under the law of having a delta-9 tetrahydrocannabinol [THC] concentration of less than 0.3 percent. The Committee is aware that DEA has developed field testing kits that can distinguish between hemp and marijuana on-the-spot. The Committee directs the DEA to continue to work to ensure State and local law enforcement have access to this field test technology so they can more efficiently conduct their drug interdiction efforts at the local level. The Committee further directs the DEA to report back to the Committee not later than 180 days after enactment of this act, and not less than every 6 months thereafter, until such time as testing kits are deployed to State and local law enforcement in the field.”
There’s also language directing USDA to explore hemp as a sustainable alternative to plastics, similar to language that’s included in the House version.
“Plastic Alternative.—The Committee recognizes the need for biobased and U.S.-grown alternatives. The Committee directs the department to explore U.S.-based hemp as a robust and dependable plastic alternative and issue a report to the Committee on how to best facilitate its cost-efficient use in government-produced or funded materials within 180 days of the passage of this act.”
There are additional USDA-specific sections that deal with hemp biotechnology and genomics research, as well as a mandate for the department to create a hemp germplasm repository at the Plant Genetics Resources Research Unit in New York.
“Hemp Cultivar Development.—The Committee encourages ARS to conduct biotechnology and genomics research in collaboration with capable institutions to elucidate the genetic control of key production and product quality traits in hemp to facilitate cultivar development. In addition, the Committee provides no less than the fiscal year 2022 level for ARS to partner with institutions already engaged in such research to conduct hemp genetic improvement research and breeding with new breeding and editing techniques.”
…
“Hemp Germplasm.—The Committee recognizes the increasing demand for hemp for a variety of uses and its growing importance as a crop for U.S. farmers. When the Nation’s hemp germplasm was destroyed in the 1980s, researchers lost access to publicly available germplasm for plant breeding purposes. The Committee directs ARS to establish and maintain a hemp germplasm repository at the Plant Genetics Resources Research Unit and provides no less than the fiscal year 2022 level for this purpose. The Committee also encourages ARS and the Plant Genetics Resources Research Unit to partner with 1890 institutions that have existing institutional capacity on hemp germplasm research, education, and extension capabilities.”
Senate appropriators also talked about the “emerging market” for various hemp-based products and said that USDA should pursue research and development to help integrate cannabis into “existing cropping, processing, and marketing systems.” The report also discourages the department from imposing new user fees on domestic hemp production and directs it to help provide additional guaranteed loans for industry stakeholders.
Hemp Production Systems.—The Committee recognizes the emerging market potential for U.S. hemp and hemp-based products for a variety of uses. The Committee directs ARS to conduct regionally-driven research, development, and stakeholder engagement to improve agronomic and agro-economic understanding of effectively integrating hemp into existing agricultural cropping, processing, and marketing systems. The Committee provides no less than the fiscal year 2022 level for this purpose. Research, engagement, and technology transfer shall be conducted in strict accordance with all applicable Federal and State authorities and regulations.
…
Proposed User Fees.—The Committee continues to reject past proposals to administratively implement new user fees to cover the government’s full cost for providing services to certain beneficiaries, including licenses for…domestic hemp production…. The Committee strongly believes that USDA should not propose new user fees without taking into account the full impact on farmers, ranchers, and beneficiaries who would be forced to contend with rapid changes in these programs and additional burdensome costs without prior notice.
…
Hemp-Based Products.—The Committee recognizes the growing interest for U.S. hemp and hemp-based products for a variety of uses and directs FCA to work with the institutions under its jurisdiction to provide access to guaranteed loans for hemp producers and businesses.
The spending bill covering the Departments of Labor, Health and Human Services and Education maintains language that advocates say unnecessarily inhibits research into controlled substances like cannabis and psilocybin. On the House side, Rep. Alexandria Ocasio-Cortez (D-NY) previously tried to remove it through an amendment, but it twice failed in floor votes.
“SEC. 507. (a) None of the funds made available in this Act may be used for any activity that promotes the legalization of any drug or other substance included in schedule I of the schedules of controlled substances established under section 202 of the Controlled Substances Act except for normal and recognized executive-congressional communications.
(b) The limitation in subsection (a) shall not apply when there is significant medical evidence of a therapeutic advantage to the use of such drug or other substance or that federally sponsored clinical trials are being conducted to determine therapeutic advantage.”
Finally, the legislation also proposes to change the names of certain federal agencies to remove stigmatizing language around drug use. For example, the committee is recommending to remove the word “abuse” from agencies like the Substance Abuse and Mental Health Services Administration (SAMHSA), simply swapping that word with “use.” The National Institute on Drug Abuse would also be renamed to National Institute on Drugs and Addiction, for example.
While the path forward for all these drug policy provisions—particularly those that Republican leadership have already identified as controversial from their end—is uncertain, their inclusion in the base bill is a promising sign to advocates and researchers. And when bicameral negotiations begin, it’s important that there’s already overlap with the House on many of the provisions.
The House-passed appropriations legislation is similarly wide-ranging, touching on topics like cannabis research barriers, impaired driving and preventing use by youth and pregnant people. There’s also language on preventing the Department of Education from penalizing universities simply because the institutions are conducting research into marijuana.
Additional sections of the House spending package cover protections for immigrants who use cannabis, freeing up marijuana-related advertising and providing the industry with access to the banking system.“
“Senate Committee Calls For Marijuana, Psychedelics And Hemp Reforms In Draft Spending LegislationPublished 20 hours ago on July 29, 2022
Senate Democrats have released a massive package of spending bills and related reports for the 2023 Fiscal Year, including numerous provisions that deal with issues such as state-level medical marijuana protections, psychedelics research and U.S. Department of Veterans Affairs (VA) cannabis policy.
The newly unveiled legislation from Senate Appropriations Committee Chairman Patrick Leahy (D-VT) contains many familiar drug policy sections, some of which overlap with spending measures that were approved in the House this month. Both chambers have also notably excluded an existing rider that has blocked Washington, D.C. from implementing a system of legal marijuana sales—a decision that’s already drawn the ire of Senate Republicans.
And while the House has previously addressed psychedelic issues through the appropriations process, this marks the first time that the Senate has included report language that urges federal agencies to promote research into the therapeutic potential of substances like psilocybin.
Advocates hoped that the Senate would insert language in the base bill that would provide broad protections for all state and U.S. territory cannabis programs, but as introduced, the legislation only maintains a longstanding rider preventing the use of Justice Department funds to interfere in medical cannabis programs.
Of course, it’s still possible that the Senate could adopt the more holistic language as an amendment down the line, as the House did again this year. But Republican appropriators have already signaled that they will put up a fight over modest cannabis reforms such as the exclusion of the D.C. marijuana rider.
Senate Appropriations Committee Vice Chairman Richard Shelby (R-AL) voiced opposition to the removal of “legacy riders” in a statement on Thursday, for example, specifically complaining that the legislation “clears the way for marijuana legalization in Washington, D.C., and allows federal funds to be used to finance needle exchange programs in the nation’s capital without restriction.”
The newly released documents have not yet been approved by the Appropriations Committee, and at this point represent a starting point for further negotiations as proposed by the chairman. It remains to be seen to what extent the panel will go through a full markup process for each individual spending bill ahead of the end of the fiscal year on September 30.
Here’s a breakdown of the drug policy provisions of the Senate Appropriations Committee spending bills and reports:
Medical marijuana programs in states and U.S. territories would continue to be protected from Justice Department interference under a rider for the Commerce, Justice, Science, and Related Agencies (CJS) spending bill that’s been annually renewed each year since 2014.
“SEC. 531. None of the funds made available under this Act to the Department of Justice may be used, with respect to any of the States of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming, or with respect to the District of Columbia, the Commonwealth of the Northern Mariana Islands, the United States Virgin Islands, Guam, or Puerto Rico, to prevent any of them from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana.”
A summary of the CJS spending legislation from the committee majority touts the provision, though it’s mischaracterized.
“This bill again contains language preventing the Justice Department from interfering with states that have medical marijuana laws, ensuring that the prescribing and dispensing of medical marijuana in those states is both legal and regulated,” the summary states. (The rider doesn’t ensure that the programs are legal or regulated; it simply restricts the use of DOJ funds to enforce the ongoing federal prohibition that in fact continues to remain on the books.)
“Patients and doctors in states that have approved medical marijuana need to know that they are safe from arrest and prosecution by the Federal government,” the summary says.
One of the more novel sections of the appropriations legislation addresses psychedelics research, with the committee urging federal health agencies to keep funding studies that look into the medical value of substances like psilocybin.
“Psychedelic Research.—The Committee encourages NIH to continue research funding for psychedelic medicines development and encourage psychedelic research at the NIH Clinical Center. The Committee also encourages NIH to continue to work with FDA in developing and supporting public private collaborations, including academic researchers and medicine developers, to advance all forms of psychedelic research for therapeutic purposes.”
Another new section addresses VA cannabis policy, with the committee expressing “concerns” about the department interfering in veterans’ medical marijuana access, including by preventing VA doctors from issuing cannabis recommendations to patients.
“Medical Cannabis.—The Committee has concerns with any effort by VA to interfere with the ability of a veteran to participate in a medicinal marijuana program approved by a State, deny any services from the Department to a veteran who is participating in such a program, and limit or interfere with the ability of a healthcare provider of the Department to make appropriate recommendations, fill out forms, or take steps to comply with such a program.”
As noted, the appropriations legislation omits what’s known as the “Harris rider,” after Rep. Andy Harris (R-MD), that has blocked D.C. from using its local dollars to allow commercial cannabis sales even though voters approved adult-use legalization in 2014.
Sen. Chris Van Hollen (D-MD), chair of the Appropriations Financial Services and General Government (FSGG) Subcommittee, highlighted that decision, saying that the bill “will increase transparency in political fundraising, strengthen our election security, remove harmful legacy riders that unfairly restrict the District of Columbia’s ability to fund reproductive services and regulate cannabis, and much more.”
While it remains to be seen whether that provision will stay out of the final package that’s delivered to the president’s desk, the mayor of D.C. did recently sign a bill that allows people to self-certify as medical cannabis patients in the District, effectively circumventing the congressional barrier. Also, for what it’s worth, President Joe Biden’s past two budget requests have maintained the Harris rider despite broad Democratic opposition.
There are several research-focused report sections dealing with marijuana. Appropriators directed federal agencies to take steps to support studies into the Schedule I substances and emphasized their ongoing concerns about research barriers under federal prohibition.
“Marijuana Research.—The Committee is concerned that marijuana policies on the Federal level and in the States (medical marijuana, recreational use, etc.) are being changed without the benefit of scientific research to help guide those decisions. NIH is encouraged to continue supporting a full range of research on the health effects of marijuana and its components, including research, to understand how marijuana policies affect public health.”
…
“Cannabis Research.—Although concrete steps have been taken towards ameliorating the regulatory and supply issues hampering cannabis research in the U.S., funding levels have not kept pace with widespread use of cannabis and substantial clinical interest in the field. Cannabis is fully legal in 18 States and the District of Columbia, effectively so in 20 others that permit some form of medical marijuana, and consumed by nearly half of American teens and adults at some time in their lives, yet there is surprisingly little information about its effects on body chemistry and cognition. Meanwhile, limited data exists on the clinical efficacy of cannabis despite this use. The Committee encourages NIH to continue to fund cannabis research, with an emphasis on medical cannabis therapeutic development for patients. The Committee encourages NIH to expand its current research agenda across its institutes, including additional research on higher potency THC, alternative cannabis formulations and extracts, and additional minor cannabinoids. The Committee also encourages NIH to continue to conduct research on the potential medical uses of cannabis, such as chronic pain, appetite stimulation, immune diseases, cancer, metabolic and digestive disorders, epilepsy, glaucoma, multiple sclerosis, sleep disorders, and a variety of mental health conditions such as anxiety and PTSD. In addition, the Committee recognizes the benefits of cross-institute collaboration in the HEAL Initiative. Therefore, the Committee urges NIH to take an integrated approach to cannabis research, including by forming a cross-institute research group.”
…
Barriers to Research.—The Committee is concerned that restrictions associated with Schedule I of the Controlled Substance Act effectively limits the amount and type of research that can be conducted on certain Schedule I drugs, especially opioids, marijuana or its component chemicals, and new synthetic drugs and analogs. At a time when we need as much information as possible about these drugs, including research on their therapeutic potential and on overdose reversal agents, we should be lowering regulatory and other barriers to conducting this research. The Committee appreciates NIDA’s completion of a report on the barriers to research that result from the classification of drugs and compounds as Schedule I substances, including the challenges researchers face as a result of limited access to sources of marijuana including dispensary products.
The spending report for the U.S. Department of Health and Human Service (HHS) also talks about exploring alternatives to opioids, which appropriators say should include studies into the therapeutic potential of kratom, a plant associated with pain-relieving qualities.
“Combating Opioid Overdoses.—According to CDC, there were more than 107,000 drug overdose deaths during the 12-month period ending in January 2022. The Committee notes and commends NIDA for its funding of research to examine the potential for kratom to reduce opioid use among people with opioid use disorder, given kratom’s reduced addiction and overdose liability as compared to opioids.”
The House spending legislation also tackles the issue of kratom research.
The new Senate proposals also contain ample report language on hemp and its derivatives like CBD, including a mandate that the Food and Drug Administration (FDA) implement enforcement discretion guidance for the marketing of the legal cannabinoid as the agency continues to look into rulemaking.
“Cannabis and Cannabis Derivatives.—The Committee notes that budget did not request additional resources for Cannabis and Cannabis Derivatives activities, and therefore directs the FDA to maintain funding levels to support regulatory activities, including developing policy, and for the FDA to continue to perform its existing regulatory responsibilities, including review of product applications, inspections, enforcement, and targeted research for cannabis-derived substances, such as cannabidiol [CBD]. Within 90 days of enactment of this Act, the FDA shall issue a policy of enforcement discretion with regard to certain products containing CBD meeting the definition of hemp as defined by section 297A of the Agricultural Marketing Act of 1964 (7 U.S.C. 1639). Such enforcement discretion shall be in effect until the FDA establishes a process for stakeholders to notify the FDA of use of CBD in products that include safety studies for intended use per product and 112 makes a determination about such product. In addition, the FDA is encouraged to consider existing and ongoing medical research related to CBD that is being undertaken pursuant to an Investigational New Drug application in the development of a regulatory pathway for CBD in products under the jurisdiction of the FDA and to ensure that any future regulatory activity does not discourage the development of new drugs. The Committee also encourages the FDA to partner with an academic institution to expand sampling studies of CBD products currently on the market.”
The CJS bill, as well as appropriations legislation for the U.S. Department of Agriculture (USDA), contains longstanding provisions to safeguard state hemp programs from interference.
“SEC. 530. None of the funds made available by this Act may be used in contravention of section 7606 (‘Legitimacy of Industrial Hemp Research’) of the Agricultural Act of 2014 (Public Law 113–79) by the Department of Justice or the Drug Enforcement Administration.”
…
“SEC. 741. None of the funds made available by this Act or any other Act may be used—
(1) in contravention of section 7606 of the Agricultural Act of 2014 (7 U.S.C. 5940), subtitle G of the Agricultural Marketing Act of 1946, or section 10114 of the Agriculture Improvement Act of 2018; or
(2) to prohibit the transportation, processing, sale, or use of hemp, or seeds of such plant, that is grown or cultivated in accordance with section 7606 of the Agricultural Act of 2014 or subtitle G of the Agricultural Marketing Act of 1946, within or outside the State in which the hemp is grown or cultivated.”
The draft also says the committee is concerned about existing regulations for the federally legal crop such as an “arbitrary” THC limit and limited industry access to certain USDA grant and insurance programs. It also encouraged DEA to continue developing field testing technology to help law enforcement distinguish hemp from marijuana.
“Hemp.—The Committee is concerned that the level of allowable THC content in hemp may be arbitrary and pose a burden on hemp producers that is not supported by scientific evidence. The Committee directs USDA to work with the Department of Health and Human Services and the Drug Enforcement Administration to study and report to Congress on whether there is scientific basis for the current limit of 0.3 percent THC in hemp and suggest alternative levels if necessary.
The Committee is concerned that producers of high value, horticultural hemp are being prevented from accessing USDA programs designed for specialty crops, including the Specialty Crop Block Grants and crop insurance. Within 90 days of enactment of this Act, the Committee directs the Secretary to establish a dual designation for hemp as a specialty crop based on the manner and purpose for which it is grown.”
…
“Hemp Testing Technology.—The Agriculture Improvement Act of 2018 (Public Law 115–334) removed hemp and its derivatives from the Controlled Substances Act (Public Law 91–513, as amended), and authorized the production, consumption, and sale of hemp and hemp-derived products in the United States. The Act requires random testing to ensure hemp meets the definition under the law of having a delta-9 tetrahydrocannabinol [THC] concentration of less than 0.3 percent. The Committee is aware that DEA has developed field testing kits that can distinguish between hemp and marijuana on-the-spot. The Committee directs the DEA to continue to work to ensure State and local law enforcement have access to this field test technology so they can more efficiently conduct their drug interdiction efforts at the local level. The Committee further directs the DEA to report back to the Committee not later than 180 days after enactment of this act, and not less than every 6 months thereafter, until such time as testing kits are deployed to State and local law enforcement in the field.”
There’s also language directing USDA to explore hemp as a sustainable alternative to plastics, similar to language that’s included in the House version.
“Plastic Alternative.—The Committee recognizes the need for biobased and U.S.-grown alternatives. The Committee directs the department to explore U.S.-based hemp as a robust and dependable plastic alternative and issue a report to the Committee on how to best facilitate its cost-efficient use in government-produced or funded materials within 180 days of the passage of this act.”
There are additional USDA-specific sections that deal with hemp biotechnology and genomics research, as well as a mandate for the department to create a hemp germplasm repository at the Plant Genetics Resources Research Unit in New York.
“Hemp Cultivar Development.—The Committee encourages ARS to conduct biotechnology and genomics research in collaboration with capable institutions to elucidate the genetic control of key production and product quality traits in hemp to facilitate cultivar development. In addition, the Committee provides no less than the fiscal year 2022 level for ARS to partner with institutions already engaged in such research to conduct hemp genetic improvement research and breeding with new breeding and editing techniques.”
…
“Hemp Germplasm.—The Committee recognizes the increasing demand for hemp for a variety of uses and its growing importance as a crop for U.S. farmers. When the Nation’s hemp germplasm was destroyed in the 1980s, researchers lost access to publicly available germplasm for plant breeding purposes. The Committee directs ARS to establish and maintain a hemp germplasm repository at the Plant Genetics Resources Research Unit and provides no less than the fiscal year 2022 level for this purpose. The Committee also encourages ARS and the Plant Genetics Resources Research Unit to partner with 1890 institutions that have existing institutional capacity on hemp germplasm research, education, and extension capabilities.”
Senate appropriators also talked about the “emerging market” for various hemp-based products and said that USDA should pursue research and development to help integrate cannabis into “existing cropping, processing, and marketing systems.” The report also discourages the department from imposing new user fees on domestic hemp production and directs it to help provide additional guaranteed loans for industry stakeholders.
Hemp Production Systems.—The Committee recognizes the emerging market potential for U.S. hemp and hemp-based products for a variety of uses. The Committee directs ARS to conduct regionally-driven research, development, and stakeholder engagement to improve agronomic and agro-economic understanding of effectively integrating hemp into existing agricultural cropping, processing, and marketing systems. The Committee provides no less than the fiscal year 2022 level for this purpose. Research, engagement, and technology transfer shall be conducted in strict accordance with all applicable Federal and State authorities and regulations.
…
Proposed User Fees.—The Committee continues to reject past proposals to administratively implement new user fees to cover the government’s full cost for providing services to certain beneficiaries, including licenses for…domestic hemp production…. The Committee strongly believes that USDA should not propose new user fees without taking into account the full impact on farmers, ranchers, and beneficiaries who would be forced to contend with rapid changes in these programs and additional burdensome costs without prior notice.
…
Hemp-Based Products.—The Committee recognizes the growing interest for U.S. hemp and hemp-based products for a variety of uses and directs FCA to work with the institutions under its jurisdiction to provide access to guaranteed loans for hemp producers and businesses.
The spending bill covering the Departments of Labor, Health and Human Services and Education maintains language that advocates say unnecessarily inhibits research into controlled substances like cannabis and psilocybin. On the House side, Rep. Alexandria Ocasio-Cortez (D-NY) previously tried to remove it through an amendment, but it twice failed in floor votes.
“SEC. 507. (a) None of the funds made available in this Act may be used for any activity that promotes the legalization of any drug or other substance included in schedule I of the schedules of controlled substances established under section 202 of the Controlled Substances Act except for normal and recognized executive-congressional communications.
(b) The limitation in subsection (a) shall not apply when there is significant medical evidence of a therapeutic advantage to the use of such drug or other substance or that federally sponsored clinical trials are being conducted to determine therapeutic advantage.”
Finally, the legislation also proposes to change the names of certain federal agencies to remove stigmatizing language around drug use. For example, the committee is recommending to remove the word “abuse” from agencies like the Substance Abuse and Mental Health Services Administration (SAMHSA), simply swapping that word with “use.” The National Institute on Drug Abuse would also be renamed to National Institute on Drugs and Addiction, for example.
While the path forward for all these drug policy provisions—particularly those that Republican leadership have already identified as controversial from their end—is uncertain, their inclusion in the base bill is a promising sign to advocates and researchers. And when bicameral negotiations begin, it’s important that there’s already overlap with the House on many of the provisions.
The House-passed appropriations legislation is similarly wide-ranging, touching on topics like cannabis research barriers, impaired driving and preventing use by youth and pregnant people. There’s also language on preventing the Department of Education from penalizing universities simply because the institutions are conducting research into marijuana.
Additional sections of the House spending package cover protections for immigrants who use cannabis, freeing up marijuana-related advertising and providing the industry with access to the banking system.“
“Senate Committee Calls For Marijuana, Psychedelics And Hemp Reforms In Draft Spending LegislationPublished 20 hours ago on July 29, 2022
Senate Democrats have released a massive package of spending bills and related reports for the 2023 Fiscal Year, including numerous provisions that deal with issues such as state-level medical marijuana protections, psychedelics research and U.S. Department of Veterans Affairs (VA) cannabis policy.
The newly unveiled legislation from Senate Appropriations Committee Chairman Patrick Leahy (D-VT) contains many familiar drug policy sections, some of which overlap with spending measures that were approved in the House this month. Both chambers have also notably excluded an existing rider that has blocked Washington, D.C. from implementing a system of legal marijuana sales—a decision that’s already drawn the ire of Senate Republicans.
And while the House has previously addressed psychedelic issues through the appropriations process, this marks the first time that the Senate has included report language that urges federal agencies to promote research into the therapeutic potential of substances like psilocybin.
Advocates hoped that the Senate would insert language in the base bill that would provide broad protections for all state and U.S. territory cannabis programs, but as introduced, the legislation only maintains a longstanding rider preventing the use of Justice Department funds to interfere in medical cannabis programs.
Of course, it’s still possible that the Senate could adopt the more holistic language as an amendment down the line, as the House did again this year. But Republican appropriators have already signaled that they will put up a fight over modest cannabis reforms such as the exclusion of the D.C. marijuana rider.
Senate Appropriations Committee Vice Chairman Richard Shelby (R-AL) voiced opposition to the removal of “legacy riders” in a statement on Thursday, for example, specifically complaining that the legislation “clears the way for marijuana legalization in Washington, D.C., and allows federal funds to be used to finance needle exchange programs in the nation’s capital without restriction.”
The newly released documents have not yet been approved by the Appropriations Committee, and at this point represent a starting point for further negotiations as proposed by the chairman. It remains to be seen to what extent the panel will go through a full markup process for each individual spending bill ahead of the end of the fiscal year on September 30.
Here’s a breakdown of the drug policy provisions of the Senate Appropriations Committee spending bills and reports:
Medical marijuana programs in states and U.S. territories would continue to be protected from Justice Department interference under a rider for the Commerce, Justice, Science, and Related Agencies (CJS) spending bill that’s been annually renewed each year since 2014.
“SEC. 531. None of the funds made available under this Act to the Department of Justice may be used, with respect to any of the States of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming, or with respect to the District of Columbia, the Commonwealth of the Northern Mariana Islands, the United States Virgin Islands, Guam, or Puerto Rico, to prevent any of them from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana.”
A summary of the CJS spending legislation from the committee majority touts the provision, though it’s mischaracterized.
“This bill again contains language preventing the Justice Department from interfering with states that have medical marijuana laws, ensuring that the prescribing and dispensing of medical marijuana in those states is both legal and regulated,” the summary states. (The rider doesn’t ensure that the programs are legal or regulated; it simply restricts the use of DOJ funds to enforce the ongoing federal prohibition that in fact continues to remain on the books.)
“Patients and doctors in states that have approved medical marijuana need to know that they are safe from arrest and prosecution by the Federal government,” the summary says.
One of the more novel sections of the appropriations legislation addresses psychedelics research, with the committee urging federal health agencies to keep funding studies that look into the medical value of substances like psilocybin.
“Psychedelic Research.—The Committee encourages NIH to continue research funding for psychedelic medicines development and encourage psychedelic research at the NIH Clinical Center. The Committee also encourages NIH to continue to work with FDA in developing and supporting public private collaborations, including academic researchers and medicine developers, to advance all forms of psychedelic research for therapeutic purposes.”
Another new section addresses VA cannabis policy, with the committee expressing “concerns” about the department interfering in veterans’ medical marijuana access, including by preventing VA doctors from issuing cannabis recommendations to patients.
“Medical Cannabis.—The Committee has concerns with any effort by VA to interfere with the ability of a veteran to participate in a medicinal marijuana program approved by a State, deny any services from the Department to a veteran who is participating in such a program, and limit or interfere with the ability of a healthcare provider of the Department to make appropriate recommendations, fill out forms, or take steps to comply with such a program.”
As noted, the appropriations legislation omits what’s known as the “Harris rider,” after Rep. Andy Harris (R-MD), that has blocked D.C. from using its local dollars to allow commercial cannabis sales even though voters approved adult-use legalization in 2014.
Sen. Chris Van Hollen (D-MD), chair of the Appropriations Financial Services and General Government (FSGG) Subcommittee, highlighted that decision, saying that the bill “will increase transparency in political fundraising, strengthen our election security, remove harmful legacy riders that unfairly restrict the District of Columbia’s ability to fund reproductive services and regulate cannabis, and much more.”
While it remains to be seen whether that provision will stay out of the final package that’s delivered to the president’s desk, the mayor of D.C. did recently sign a bill that allows people to self-certify as medical cannabis patients in the District, effectively circumventing the congressional barrier. Also, for what it’s worth, President Joe Biden’s past two budget requests have maintained the Harris rider despite broad Democratic opposition.
There are several research-focused report sections dealing with marijuana. Appropriators directed federal agencies to take steps to support studies into the Schedule I substances and emphasized their ongoing concerns about research barriers under federal prohibition.
“Marijuana Research.—The Committee is concerned that marijuana policies on the Federal level and in the States (medical marijuana, recreational use, etc.) are being changed without the benefit of scientific research to help guide those decisions. NIH is encouraged to continue supporting a full range of research on the health effects of marijuana and its components, including research, to understand how marijuana policies affect public health.”
…
“Cannabis Research.—Although concrete steps have been taken towards ameliorating the regulatory and supply issues hampering cannabis research in the U.S., funding levels have not kept pace with widespread use of cannabis and substantial clinical interest in the field. Cannabis is fully legal in 18 States and the District of Columbia, effectively so in 20 others that permit some form of medical marijuana, and consumed by nearly half of American teens and adults at some time in their lives, yet there is surprisingly little information about its effects on body chemistry and cognition. Meanwhile, limited data exists on the clinical efficacy of cannabis despite this use. The Committee encourages NIH to continue to fund cannabis research, with an emphasis on medical cannabis therapeutic development for patients. The Committee encourages NIH to expand its current research agenda across its institutes, including additional research on higher potency THC, alternative cannabis formulations and extracts, and additional minor cannabinoids. The Committee also encourages NIH to continue to conduct research on the potential medical uses of cannabis, such as chronic pain, appetite stimulation, immune diseases, cancer, metabolic and digestive disorders, epilepsy, glaucoma, multiple sclerosis, sleep disorders, and a variety of mental health conditions such as anxiety and PTSD. In addition, the Committee recognizes the benefits of cross-institute collaboration in the HEAL Initiative. Therefore, the Committee urges NIH to take an integrated approach to cannabis research, including by forming a cross-institute research group.”
…
Barriers to Research.—The Committee is concerned that restrictions associated with Schedule I of the Controlled Substance Act effectively limits the amount and type of research that can be conducted on certain Schedule I drugs, especially opioids, marijuana or its component chemicals, and new synthetic drugs and analogs. At a time when we need as much information as possible about these drugs, including research on their therapeutic potential and on overdose reversal agents, we should be lowering regulatory and other barriers to conducting this research. The Committee appreciates NIDA’s completion of a report on the barriers to research that result from the classification of drugs and compounds as Schedule I substances, including the challenges researchers face as a result of limited access to sources of marijuana including dispensary products.
The spending report for the U.S. Department of Health and Human Service (HHS) also talks about exploring alternatives to opioids, which appropriators say should include studies into the therapeutic potential of kratom, a plant associated with pain-relieving qualities.
“Combating Opioid Overdoses.—According to CDC, there were more than 107,000 drug overdose deaths during the 12-month period ending in January 2022. The Committee notes and commends NIDA for its funding of research to examine the potential for kratom to reduce opioid use among people with opioid use disorder, given kratom’s reduced addiction and overdose liability as compared to opioids.”
The House spending legislation also tackles the issue of kratom research.
The new Senate proposals also contain ample report language on hemp and its derivatives like CBD, including a mandate that the Food and Drug Administration (FDA) implement enforcement discretion guidance for the marketing of the legal cannabinoid as the agency continues to look into rulemaking.
“Cannabis and Cannabis Derivatives.—The Committee notes that budget did not request additional resources for Cannabis and Cannabis Derivatives activities, and therefore directs the FDA to maintain funding levels to support regulatory activities, including developing policy, and for the FDA to continue to perform its existing regulatory responsibilities, including review of product applications, inspections, enforcement, and targeted research for cannabis-derived substances, such as cannabidiol [CBD]. Within 90 days of enactment of this Act, the FDA shall issue a policy of enforcement discretion with regard to certain products containing CBD meeting the definition of hemp as defined by section 297A of the Agricultural Marketing Act of 1964 (7 U.S.C. 1639). Such enforcement discretion shall be in effect until the FDA establishes a process for stakeholders to notify the FDA of use of CBD in products that include safety studies for intended use per product and 112 makes a determination about such product. In addition, the FDA is encouraged to consider existing and ongoing medical research related to CBD that is being undertaken pursuant to an Investigational New Drug application in the development of a regulatory pathway for CBD in products under the jurisdiction of the FDA and to ensure that any future regulatory activity does not discourage the development of new drugs. The Committee also encourages the FDA to partner with an academic institution to expand sampling studies of CBD products currently on the market.”
The CJS bill, as well as appropriations legislation for the U.S. Department of Agriculture (USDA), contains longstanding provisions to safeguard state hemp programs from interference.
“SEC. 530. None of the funds made available by this Act may be used in contravention of section 7606 (‘Legitimacy of Industrial Hemp Research’) of the Agricultural Act of 2014 (Public Law 113–79) by the Department of Justice or the Drug Enforcement Administration.”
…
“SEC. 741. None of the funds made available by this Act or any other Act may be used—
(1) in contravention of section 7606 of the Agricultural Act of 2014 (7 U.S.C. 5940), subtitle G of the Agricultural Marketing Act of 1946, or section 10114 of the Agriculture Improvement Act of 2018; or
(2) to prohibit the transportation, processing, sale, or use of hemp, or seeds of such plant, that is grown or cultivated in accordance with section 7606 of the Agricultural Act of 2014 or subtitle G of the Agricultural Marketing Act of 1946, within or outside the State in which the hemp is grown or cultivated.”
The draft also says the committee is concerned about existing regulations for the federally legal crop such as an “arbitrary” THC limit and limited industry access to certain USDA grant and insurance programs. It also encouraged DEA to continue developing field testing technology to help law enforcement distinguish hemp from marijuana.
“Hemp.—The Committee is concerned that the level of allowable THC content in hemp may be arbitrary and pose a burden on hemp producers that is not supported by scientific evidence. The Committee directs USDA to work with the Department of Health and Human Services and the Drug Enforcement Administration to study and report to Congress on whether there is scientific basis for the current limit of 0.3 percent THC in hemp and suggest alternative levels if necessary.
The Committee is concerned that producers of high value, horticultural hemp are being prevented from accessing USDA programs designed for specialty crops, including the Specialty Crop Block Grants and crop insurance. Within 90 days of enactment of this Act, the Committee directs the Secretary to establish a dual designation for hemp as a specialty crop based on the manner and purpose for which it is grown.”
…
“Hemp Testing Technology.—The Agriculture Improvement Act of 2018 (Public Law 115–334) removed hemp and its derivatives from the Controlled Substances Act (Public Law 91–513, as amended), and authorized the production, consumption, and sale of hemp and hemp-derived products in the United States. The Act requires random testing to ensure hemp meets the definition under the law of having a delta-9 tetrahydrocannabinol [THC] concentration of less than 0.3 percent. The Committee is aware that DEA has developed field testing kits that can distinguish between hemp and marijuana on-the-spot. The Committee directs the DEA to continue to work to ensure State and local law enforcement have access to this field test technology so they can more efficiently conduct their drug interdiction efforts at the local level. The Committee further directs the DEA to report back to the Committee not later than 180 days after enactment of this act, and not less than every 6 months thereafter, until such time as testing kits are deployed to State and local law enforcement in the field.”
There’s also language directing USDA to explore hemp as a sustainable alternative to plastics, similar to language that’s included in the House version.
“Plastic Alternative.—The Committee recognizes the need for biobased and U.S.-grown alternatives. The Committee directs the department to explore U.S.-based hemp as a robust and dependable plastic alternative and issue a report to the Committee on how to best facilitate its cost-efficient use in government-produced or funded materials within 180 days of the passage of this act.”
There are additional USDA-specific sections that deal with hemp biotechnology and genomics research, as well as a mandate for the department to create a hemp germplasm repository at the Plant Genetics Resources Research Unit in New York.
“Hemp Cultivar Development.—The Committee encourages ARS to conduct biotechnology and genomics research in collaboration with capable institutions to elucidate the genetic control of key production and product quality traits in hemp to facilitate cultivar development. In addition, the Committee provides no less than the fiscal year 2022 level for ARS to partner with institutions already engaged in such research to conduct hemp genetic improvement research and breeding with new breeding and editing techniques.”
…
“Hemp Germplasm.—The Committee recognizes the increasing demand for hemp for a variety of uses and its growing importance as a crop for U.S. farmers. When the Nation’s hemp germplasm was destroyed in the 1980s, researchers lost access to publicly available germplasm for plant breeding purposes. The Committee directs ARS to establish and maintain a hemp germplasm repository at the Plant Genetics Resources Research Unit and provides no less than the fiscal year 2022 level for this purpose. The Committee also encourages ARS and the Plant Genetics Resources Research Unit to partner with 1890 institutions that have existing institutional capacity on hemp germplasm research, education, and extension capabilities.”
Senate appropriators also talked about the “emerging market” for various hemp-based products and said that USDA should pursue research and development to help integrate cannabis into “existing cropping, processing, and marketing systems.” The report also discourages the department from imposing new user fees on domestic hemp production and directs it to help provide additional guaranteed loans for industry stakeholders.
Hemp Production Systems.—The Committee recognizes the emerging market potential for U.S. hemp and hemp-based products for a variety of uses. The Committee directs ARS to conduct regionally-driven research, development, and stakeholder engagement to improve agronomic and agro-economic understanding of effectively integrating hemp into existing agricultural cropping, processing, and marketing systems. The Committee provides no less than the fiscal year 2022 level for this purpose. Research, engagement, and technology transfer shall be conducted in strict accordance with all applicable Federal and State authorities and regulations.
…
Proposed User Fees.—The Committee continues to reject past proposals to administratively implement new user fees to cover the government’s full cost for providing services to certain beneficiaries, including licenses for…domestic hemp production…. The Committee strongly believes that USDA should not propose new user fees without taking into account the full impact on farmers, ranchers, and beneficiaries who would be forced to contend with rapid changes in these programs and additional burdensome costs without prior notice.
…
Hemp-Based Products.—The Committee recognizes the growing interest for U.S. hemp and hemp-based products for a variety of uses and directs FCA to work with the institutions under its jurisdiction to provide access to guaranteed loans for hemp producers and businesses.
The spending bill covering the Departments of Labor, Health and Human Services and Education maintains language that advocates say unnecessarily inhibits research into controlled substances like cannabis and psilocybin. On the House side, Rep. Alexandria Ocasio-Cortez (D-NY) previously tried to remove it through an amendment, but it twice failed in floor votes.
“SEC. 507. (a) None of the funds made available in this Act may be used for any activity that promotes the legalization of any drug or other substance included in schedule I of the schedules of controlled substances established under section 202 of the Controlled Substances Act except for normal and recognized executive-congressional communications.
(b) The limitation in subsection (a) shall not apply when there is significant medical evidence of a therapeutic advantage to the use of such drug or other substance or that federally sponsored clinical trials are being conducted to determine therapeutic advantage.”
Finally, the legislation also proposes to change the names of certain federal agencies to remove stigmatizing language around drug use. For example, the committee is recommending to remove the word “abuse” from agencies like the Substance Abuse and Mental Health Services Administration (SAMHSA), simply swapping that word with “use.” The National Institute on Drug Abuse would also be renamed to National Institute on Drugs and Addiction, for example.
While the path forward for all these drug policy provisions—particularly those that Republican leadership have already identified as controversial from their end—is uncertain, their inclusion in the base bill is a promising sign to advocates and researchers. And when bicameral negotiations begin, it’s important that there’s already overlap with the House on many of the provisions.
The House-passed appropriations legislation is similarly wide-ranging, touching on topics like cannabis research barriers, impaired driving and preventing use by youth and pregnant people. There’s also language on preventing the Department of Education from penalizing universities simply because the institutions are conducting research into marijuana.
Additional sections of the House spending package cover protections for immigrants who use cannabis, freeing up marijuana-related advertising and providing the industry with access to the banking system.“
From 6/27/22:
https://www.otcmarkets.com/filing/html?id=15912881&guid=3Lk-kFxzfuIjJth
“GEOVAX LABS, INC.
21,412,124 Shares of Common Stock
This prospectus relates to the resale of up to an aggregate of 21,412,124 shares (the “Common Shares”) of our common stock, par value $0.001 per share (the “Common Stock”), consisting of (i) 9,090,910 shares of Common Stock issuable upon the exercise of pre-funded warrants issued in the Private Placement (the “Pre-Funded Warrant”), (ii) 12,121,214 shares of Common Stock issuable upon the exercise of preferred investment options issued in the Private Placement at an exercise price of $1.65 per share (the “Preferred Investment Option”), (iii) 128,000 shares of Common Stock issuable upon the exercise of a warrant issued in a public offering in September 2020 at an exercise price of $5.50 per share (the “2020 Common Warrant”) and (iv) 72,000 shares of Common Stock issuable upon the exercise of a warrant issued in a public offering in February 2021 at an exercise price of $6.875 per share (the “2021 Common Warrant” and together with the Pre-Funded Warrant, the Preferred Investment Option and the 2020 Common Warrant, the “Warrants” and, collectively with the Pre-Funded Warrant and Common Shares, the “Securities”). This prospectus relates to the resale of up to an aggregate of 21,212,124 Common Shares issuable upon the exercise of the Pre-Funded Warrant and the Preferred Investment Option by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (“Armistice”), 128,000 Common Shares issuable upon the exercise of the 2020 Common Warrant by Maxim Partners LLC (“Maxim Partners” and together with Armistice, the “Selling Stockholders”) and 72,000 Common Shares issuable upon the exercise of the 2021 Common Warrant by Maxim Partners.
We will not receive any proceeds from the sale of the Common Shares covered by this prospectus by the Selling Stockholders. All net proceeds from the sale of the Common Shares covered by this prospectus will go to the Selling Stockholders. However, we may receive the proceeds from any exercise of each of the Preferred Investment Option, the 2020 Common Warrant or the 2021 Common Warrant. See “Use of Proceeds.”
The Selling Stockholders may sell all or a portion of the Common Shares stock covered by this prospectus from time to time in market transactions through any market on which our shares of common stock are then traded, in negotiated transactions or otherwise, and at prices and on terms that will be determined by the then prevailing market price or at negotiated prices directly or through a broker or brokers, who may act as agent or as principal or by a combination of such methods of sale. See “Plan of Distribution.”
Our common stock and the warrants we issued to investors in a September 2020 public offering (the “September 2020 Warrants”) are listed on the Nasdaq Capital Market under the symbols “GOVX” and “GOVXW,” respectively. On June 10, 2022, the last reported sale price of our common stock was $1.42 per share and the last reported sale price of the September 2020 Warrants was $0.56 per warrant.
Investing in our shares of common stock involves a high degree of risk. The risks are described in the “Risk Factors” section beginning on page 6 of this prospectus. You should also consider the risk factors described or referred to in any applicable prospectus supplement before investing in these securities.
Neither the Securities and Exchange Commission (“SEC”) nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.
The date of this prospectus is June 27, 2022.
“
“Unless otherwise indicated, the number of shares of our common stock outstanding prior to this offering is based on 12,547,829 shares of common stock outstanding as of June 10, 2022, and exclude as of such date:
?
9,090,910 shares of common stock issuable upon the exercise of the Private Pre-Funded Warrants with exercise prices of $0.0001 per share;
?
12,121,214 shares of common stock issuable upon the exercise of the Preferred Investment Options with exercise prices of $1.65 per share;
?
5,884,115 shares of common stock issuable upon the exercise of other outstanding warrants with a weighted average exercise price of $4.19 per share; and
?
1,500,000 shares of common stock which are reserved for issuance under our 2020 Stock Incentive Plan, of which 962,300 shares of common stock are issuable upon exercise of outstanding options at an average exercise price of $3.18 per share.”
https://www.otcmarkets.com/stock/GOVX/disclosure
Share price range Friday: 2.17 - 3.39
182 million shares traded. The 962,300 may have been sold into the market at $3.18, as well as 12 million may have been sold beginning from $1.65 per share. That’s 13 million in sell volume. Plus 9 million in prefunded warrants, totaling 22 million in shares added to the OS for a grand total today of 34 million, with about 6 million at $4.19 per share still to go, 128 k at $5.50 and 72k at $6.875. All imo as per my reading of the document.
Monday/Tuesday looking for gains here, 6 month consolidation over:
“Bringing Shape's next-gen content creation abilities into the Company's portfolio of gaming solutions are intended to accelerate the Company's metaverse production capabilities, provide cross-selling opportunities across business units and allow further gaming intellectual property development and speed to market. Shape will function as a business unit within the Company and Shape's management team will continue to lead the studio.
"Acquiring Shape accelerates Alpha's positioning as a global leader in metaverse technology, NFT content creation and Web3 gaming. Shape's reputation and skill sets are important assets to add to Alpha's growing portfolio of gaming 'software as a service' applications and metaverse capabilities. The Acquisition will allow the Company to both invest in Shape's growth and capacity while also giving Alpha the ability to build recognized metaverse gaming experiences in-house," stated Brian Wilneff, CEO of Alpha.
A leader in metaverse development since inception in 2018, Shape was founded by Vancouver VR/AR Association co-presidents, Alex Chuang and Dan Burgar. Alex Chuang is a BC Business '30 under 30' award winner and founded Launch Academy, Western Canada's largest tech incubator, which has helped its members raise over $2 Billion since inception. Dan Burgar is an official 'top 15 technology voice' on LinkedIn and a leading voice generally in the global metaverse community.
"The metaverse is anticipated to be worth between $8 trillion to $13 trillion by 2030. By combining Shape's talent and experience in Web3 with the existing gaming portfolio and user base of Alpha, Alpha will further its expansion into Web3 and position itself to capitalize on the unique tipping point in technology disruption," stated James Basnett, CEO of Shape.
In connection with the Acquisition, the Company also announces that 3,500,000 performance warrants that were issued on September 1, 2020 to certain consultants have vested in accordance with their terms and become exercisable.”
From 5/5 to 8/5 is about 60 trading days with average volume about 15 to 30 k.
15 k x 60 = 900,000 shares
30 k x 60 = 1.8 million shares.
So if 50% of the warrants are gone maybe the other 50% will hold
Closed at 2.74 and that’s where it should go Monday, to 74. Or the market is rigged. 180 million shares traded 12 million Outstanding, 12 million are not held over the weekend? 50 million ghost shares aren’t right now? Any demand over total shares available should send the price higher therefore since there are zero shares to sell. Level 2 right now 31 k on the ask at 2.74. I hope this goes to 74 and your millions that you never made are worth the 70 grand.